Language
U.S. House of Representatives
Every sitting is free to watch on Polyfact, live and on replay, no account needed.
Latest update 57 days ago
What is said in the sittings, update by update, the latest first. Each update opens the video at the second it was said.
The final exchanges address post‑HR 1 hospital and L&D closures, protections against abusive vision and dialysis benefit practices, stabilization of radiation oncology and Alzheimer’s diagnostic coverage, and the broader need for data‑driven physician payment reform before the chair enters documents into the record, sets deadlines for written questions, and adjourns the hearing.
In this chapter
Members focus on expanding access and reducing costs through diabetic shoe certification reforms, pharmacist‑delivered preventive and acute care under ECAPS, fairer payment for high‑supply‑cost office procedures, and hybrid primary‑care payment models, linking these to independent practice viability, underserved communities, and regulation of vision benefit managers.
In this chapter
The discussion turns to how hospital and private‑equity consolidation, site‑of‑service payment differentials, and MIPS burdens drive independent practices out of business, with members probing how the Patients First Act, fair supply‑cost reimbursement, specialist‑driven quality metrics, and targeted cybersecurity support for rural hospitals can address MACRA’s flaws while strengthening system resilience.
In this chapter
Members and witnesses examine how declining, inflation‑lagging Medicare physician payments, MACRA shortcomings, and GOP‑driven coverage cuts affect access to primary care, dermatology, and maternity services, while debating the Patients First Act, Rural Obstetrics Readiness Act, ECAPS pharmacist bill, and Alzheimer’s screening coverage to stabilize practices and improve rural and cognitive care.
In this chapter
Invited witnesses present sector perspectives on healthcare cybersecurity, Medicare recognition of pharmacist services, physician fee schedule cuts, primary care underfunding, rural obstetric unit closures, and the need for a coordinated national epilepsy plan, grounding support for the specific bills under review.
In this chapter
The chair and party leaders formally open the Health Subcommittee hearing, outline the agenda centered on Medicare physician payment reforms and multiple bipartisan health bills, and establish witness procedures and panel composition.
In this chapter
The hearing closes with questions on expanding trial access for underrepresented communities, safeguards for novel biomarkers, bipartisan clinical trial modernization bills aligned with Operation Trailblazer, and the need for coherent congressional signals and stable, well-resourced FDA leadership, before final exchanges on FDA turmoil, communication improvements, and formal adjournment instructions.
In this chapter
Members probe how to spur T1D device innovation, reduce rare disease burdens with digital tools and real-world data, and support young scientists amid grant cuts and OMB’s proposed termination rules, while also examining non-animal testing methodologies, biosimilar adoption and insulin affordability, China’s expanding dominance in oncology and vaccine trials, and the risks of politicizing CDC and FDA advisory processes.
In this chapter
Discussion turns to T1D screening legislation, DEI and decentralized models for more representative enrollment, the national security implications of cuts to NIH and FDA and loss of scientific talent, strategies to improve rare disease review consistency, and pharmaceutical patent evergreening, with witnesses stressing stable public funding, transparent FDA standards, and reforms to align incentives with genuine innovation.
In this chapter
Members question witnesses on expedited and risk-tiered IND pathways, hub-and-spoke and telehealth models to expand rural and underserved trial access, OMB’s proposed grant rule and its threat to scientific independence, psychedelics guidance, the central role of NIH in drug discovery, and how China’s industrial policy and limited FDA inspection of foreign sites affect U.S. competitiveness and security.
In this chapter
Expert witnesses present data on early-stage trials shifting to China, argue that IND preparation requirements and fragmented FDA processes drive first-in-human studies overseas, and call for risk-based IND standards, phase 1 capacity building, patient-centered regulation for T1D and cell therapies, stronger oversight of foreign trials, and measures to mitigate biosecurity and strategic dependence on China.
In this chapter
Members debate mandatory serialization and DEA reporting for pill presses versus impacts on legitimate users and criminal exposure, then advance H.R. 5880, authorize technical changes, and briefly adjourn the subcommittee.
The Chair introduces H.R. 8005 with an amendment in the nature of a substitute to target counterfeit fentanyl pills and strengthen DEA planning and penalties, as the Ranking Member argues the measure is redundant and over-penalizing before the amended bill is forwarded to the full committee.
In this chapter
The Chair presents H.R. 7184 to close loopholes on illicit pill press imports, while the Ranking Member raises concerns about expanded DEA authority and incremental penalties before the subcommittee advances the bill to the full committee.
In this chapter
Chairs and ranking members outline the hearing’s focus on preserving U.S. leadership in biomedical innovation, the role of FDA user fee reauthorization, concerns over politicization and staff cuts at FDA and NIH, and competition from China, before setting ground rules and introducing the witness panel.
In this chapter
The Chair and senior members outline the markup agenda on three anti-drug bills, describe their intended functions against fentanyl and counterfeit pills, and contrast enforcement-focused approaches with calls for expanded treatment, harm reduction, and a Cure Hepatitis C strategy.
In this chapter
Dr. Schrier and Dr. Miller-Meeks detail how extensive Medicare Advantage prior authorization requirements delay or block medically necessary care, contrast prior auth volumes between traditional Medicare and MA, and argue the bill’s electronic prior auth, transparency, and clear timelines are essential to put patients and doctors ahead of insurers.
The clerk reports H.R. 3514 and Dr. Joyce describes the bipartisan Improving Seniors’ Timely Access to Care Act, emphasizing its broad support and provisions to standardize and digitize prior authorization in Medicare Advantage, set timeliness standards, and increase oversight to speed seniors’ access to care.
After the chair opens debate, Ranking Member Pallone argues that requiring on-site cash price postings for many procedure codes could confuse insured patients and provide a misleading sense of transparency, and he urges a no vote before the subcommittee nonetheless approves forwarding H.R. 9390 to the full committee.
The clerk reads in H.R. 9390 and Dr. Miller-Meeks outlines her Prices on the Wall Act of 2026, mandating that from 2028 hospitals and specified facilities visibly post discounted cash or comparable prices for commonly shoppable services to improve healthcare price transparency and patient decision-making.
Ranking Member DeGette and Dr. Miller-Meeks describe how opaque and burdensome prior authorization delays or denies needed care, provide concrete patient and provider examples, and both urge colleagues to support H.R. 9396, which is then approved for referral to the full committee.
The chair explains H.R. 9396, requiring health plans to publicly report prior authorization approval and denial rates so consumers can compare plans’ practices and choose accordingly, and urges support to advance the bill from subcommittee to full committee.
The final exchanges address plan-level denial and prior authorization metrics, medical loss ratio transparency, NADAC-based drug pricing and 340B opacity, concerns about AI in prior auth, and situate transparency amid broader affordability and coverage challenges before the chair enters documents into the record, sets deadlines for written questions, and formally adjourns the hearing.
In this chapter
Questioning centers on private equity roll-ups, leverage, and sale-leasebacks, broader corporate takeover of care, consolidation’s impact on bargaining power and costs, concrete employer savings from using claims and price data, and Medicare Advantage marketing and broker incentives, including calls to cap and reform MA broker compensation and expand MA transparency to protect seniors.
In this chapter
Members probe barriers to patient record access, rural and safety-net hospital vulnerability, under-enforcement of hospital price transparency rules, the role of subsidies versus transparency in rural stability, bipartisan consumer-facing proposals like Patients Deserve Price Tags and CHECK, and how stronger penalties, real-time interoperability, and employer access rights could make transparency meaningful.
In this chapter
Members question witnesses on price variation, consolidation, site-of-service and site-neutral payment reforms, ownership and prior authorization metrics, Medicaid and ACA subsidy cuts versus transparency, employer data use in plan design, vertical integration, AI-enabled consumer tools, and the limits of transparency alone to discipline costs.
In this chapter
Expert witnesses from Turquoise Health, employer coalitions, AEI, Brown University, and Families USA describe the current state of hospital and payer machine-readable files, employer barriers to claims data, extreme price variation driven by consolidation and private equity, and argue that transparency on prices, ownership, prior authorization, and MA must be paired with site-neutral payments and anti-competitive contracting reforms.
In this chapter
The chair and party leaders open the hearing, frame the focus on codifying Trump-era price transparency rules and new bills like the Lower Costs, More Transparency Act and Patients Deserve Price Tags, and set competing narratives about Medicaid cuts, ACA subsidies, and the impact of prior GOP legislation on coverage and costs before introducing the witness panel.
In this chapter
The search covers the sittings held more than two weeks ago. A Polyfact subscription searches every sitting as soon as it is transcribed.
U.S. House of Representatives broadcasts the sittings of the House Energy and Commerce Subcommittee on Health. Polyfact shows each one live, keeps it as a replay with its transcript and links its key moments to the second they were said.
16 sittings on Polyfact since 11 June 2025
Polyfact records and transcribes the sittings and committee hearings of United States's parliaments. A speaker is named only once their identity is confirmed, by the official record or by a person; automatic guesses are left out.
On Polyfact, free and without an account: a sitting on air is marked live in the schedule above, and each sitting stays available as a replay.
Yes. Watching the sittings on Polyfact is free and needs no account. A Polyfact subscription, which you can try for free, adds the full transcripts as soon as they are ready, search across every sitting and alerts on your topics.
On each sitting's page on Polyfact, speaker by speaker, with its key moments one click from the second they were said. The search on this page covers the sittings held more than two weeks ago.
With a Polyfact plan you read every sitting as soon as it is transcribed, ask questions to the video assistant and get an alert as soon as your topics come up.
14-day free trial. A card is required, nothing is charged for 14 days, and you can cancel anytime.
Updated
'%20d='m0%200%2016%2011h61%2061%2061%2061%2060L47%2037h61%2061%2060%2061L16%2063h61%2061%2061%2061%2060L47%2089h61%2061%2060%2061L16%20115h61%2061%2061%2061%2060L47%20141h61%2061%2060%2061L16%20166h61%2061%2061%2061%2060L47%20192h61%2061%2060%2061L16%20218h61%2061%2061%2061%2060z'/%3e%3c/svg%3e)